Literature DB >> 23038103

Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex.

Zhijian Duan1, June X Zou, Ping Yang, Yuzhuo Wang, Alexander D Borowsky, Allen C Gao, Hong-Wu Chen.   

Abstract

BACKGROUND: Chromatin regulators ANCCA and EZH2 are overexpressed in prostate cancer and play crucial roles in androgen-stimulated and castration-refractory prostate tumor growth and survival. However, how their expression is regulated in the tumors and whether they play a role in prostate development remains unclear.
METHODS: Prostate tissue from different developmental stages of mouse and human were examined by IHC, qRT-PCR and Western for expression of ANCCA, EZH2, and Ki-67. Animals were castrated and T-implanted for the expression response in normal prostate and tumors. siRNA knockdown and ChIP were performed for the mechanism of ANCCA regulation of EZH2.
RESULTS: In contrast to their very low level expression in adult prostate, ANCCA and EZH2 are strongly expressed in the epithelium and mesenchyme of mouse and human UGS. Their expression becomes more restricted to epithelial cells during later development and displays a second peak during puberty, which correlates with the proliferative status of the epithelium. Importantly, their expression in normal prostate and tumors is strongly suppressed by castration and markedly induced by testosterone replacement. While androgen suppresses EZH2 in CRPC cells, in LNCaP cells, physiological concentrations of androgen stimulate expression of PRC2 genes (EZH2, SUZ12, and EED), which is mediated by androgen-induced ANCCA and involves E2F and histone H3K4me3 methylase MLL1 complex.
CONCLUSION: EZH2 and ANCCA are androgen regulated and strongly expressed in early prostate morphogenesis and during puberty, suggesting their important role in prostate development. Regulation of EZH2 by ANCCA emphasizes bromodomain protein ANCCA as a potential therapeutic target against prostate cancer.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23038103     DOI: 10.1002/pros.22587

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  21 in total

1.  Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its correlation with tumor progression and poor prognosis.

Authors:  Pan Shang; Fanling Meng; Yunduo Liu; Xiuwei Chen
Journal:  Tumour Biol       Date:  2015-05-02

Review 2.  Regulation and role of post-translational modifications of enhancer of zeste homologue 2 in cancer development.

Authors:  Haiqi Lu; Guangliang Li; Chenyi Zhou; Wei Jin; Xiaoling Qian; Zhuo Wang; Hongming Pan; Hongchuan Jin; Xian Wang
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

Review 3.  Biological function and histone recognition of family IV bromodomain-containing proteins.

Authors:  Jonathan T Lloyd; Karen C Glass
Journal:  J Cell Physiol       Date:  2017-06-13       Impact factor: 6.384

4.  Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance.

Authors:  June X Zou; Zhijian Duan; Junjian Wang; Alex Sokolov; Jianzhen Xu; Christopher Z Chen; Jian Jian Li; Hong-Wu Chen
Journal:  Mol Cancer Res       Date:  2014-01-03       Impact factor: 5.852

Review 5.  DNA methylation as a dynamic regulator of development and disease processes: spotlight on the prostate.

Authors:  Kimberly P Keil; Chad M Vezina
Journal:  Epigenomics       Date:  2015       Impact factor: 4.778

6.  Disulfide bridge formation influences ligand recognition by the ATAD2 bromodomain.

Authors:  Jamie C Gay; Brian E Eckenroth; Chiara M Evans; Cassiano Langini; Samuel Carlson; Jonathan T Lloyd; Amedeo Caflisch; Karen C Glass
Journal:  Proteins       Date:  2018-12-27

7.  Catalog of mRNA expression patterns for DNA methylating and demethylating genes in developing mouse lower urinary tract.

Authors:  Kimberly P Keil; Helene M Altmann; Vatsal Mehta; Lisa L Abler; Erik A Elton; Chad M Vezina
Journal:  Gene Expr Patterns       Date:  2013-08-03       Impact factor: 1.224

8.  The ATAD2 bromodomain binds different acetylation marks on the histone H4 in similar fuzzy complexes.

Authors:  Cassiano Langini; Amedeo Caflisch; Andreas Vitalis
Journal:  J Biol Chem       Date:  2017-08-10       Impact factor: 5.157

9.  Observed bromodomain flexibility reveals histone peptide- and small molecule ligand-compatible forms of ATAD2.

Authors:  Guillaume Poncet-Montange; Yanai Zhan; Jennifer P Bardenhagen; Alessia Petrocchi; Elisabetta Leo; Xi Shi; Gilbert R Lee; Paul G Leonard; Mary K Geck Do; Mario G Cardozo; Jannik N Andersen; Wylie S Palmer; Philip Jones; John E Ladbury
Journal:  Biochem J       Date:  2015-03-01       Impact factor: 3.857

Review 10.  Drug discovery in advanced prostate cancer: translating biology into therapy.

Authors:  Timothy A Yap; Alan D Smith; Roberta Ferraldeschi; Bissan Al-Lazikani; Paul Workman; Johann S de Bono
Journal:  Nat Rev Drug Discov       Date:  2016-07-22       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.